公开(公告)号：US20240228437A1

公开(公告)日：2024-07-11

申请号：US18557255

申请日：2022-04-25

申请人： Takeda Pharmaceutical Limited Company

发明人： Masatoshi YAMADA ,  Sayuri HIRANO ,  Osamu YABE ,  Yuichi KAJITA ,  Tsuneo ODA ,  Takashi ABE ,  Hironori YAMASHITA

IPC分类号： C07D207/14

CPC分类号： C07D207/14

摘要： The present invention provides a method suitable for industrial production of a compound of formula (V): (V) comprising a step of subjecting a compound (IV) to an asymmetric reductive amination reaction in the presence of a metal complex comprising a chiral ligand and subjecting this product to purification using salt formation with N-(4-methylbenzene-1-sulfonyl)-L-phenylalanine.

公开(公告)号：US20100129790A1

公开(公告)日：2010-05-27

申请号：US11884546

申请日：2006-02-16

申请人： Hiroshi Sawada ,  Ikuo Mori ,  Kenji Takami

发明人： Hiroshi Sawada ,  Ikuo Mori ,  Kenji Takami

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158

摘要： It is intended to provide a rapid, simple and noninvasive novel in vivo method for determining phospholipidosis (PLsis) by detecting a PLsis marker gene. More specifically, it is intended to provide a method for determining phospholipidosis in a mammal comprising the step of detecting change in expression of one or more genes whose expression changes correlated with the onset of phospholipidosis in a sample collected from the mammal, in which at least one of the genes comprises a base sequence identical or substantially identical to the base sequence represented by any of SEQ ID NO: n (wherein n is an odd number between 1 and 57, an integer number between 59 and 63, an even number between 64 and 98, 100 or 101.)

摘要翻译： 旨在提供通过检测PLsis标记基因来测定磷脂病（PLsis）的快速，简单和无创新型体内新方法。 更具体地说，本发明提供一种用于测定哺乳动物中的磷脂病的方法，包括检测从哺乳动物采集的样品中表达变化与磷脂症发生相关的一种或多种基因的表达变化的步骤，其中至少 基因之一包含与SEQ ID NO：n中任一个表示的碱基序列相同或基本相同的碱基序列（其中n为1至57之间的奇数，59至63之间的整数，64之间的偶数 和98,100或101.）

公开(公告)号：US20240165092A1

公开(公告)日：2024-05-23

申请号：US18553348

申请日：2022-04-01

申请人： Takeda Pharmaceutical Limited Company

发明人： Haruhide KIMURA ,  Motohisa SUZUKI ,  James CRONICAN

IPC分类号： A61K31/445 ,  A61P11/00 ,  A61P39/00

CPC分类号： A61K31/445 ,  A61P11/00 ,  A61P39/00

摘要： A method for recovering post operation in a subject in need thereof is disclosed, comprising administering to the subject an effective amount of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate (Compound (I)), or a salt thereof.

公开(公告)号：US09693962B2

公开(公告)日：2017-07-04

申请号：US14405310

申请日：2013-05-28

申请人： Takeda Pharmaceutical Company Limited

发明人： Tetsuya Kawano

IPC分类号： A61K9/20 ,  A61K31/4439 ,  A61K31/616 ,  A61K9/28

CPC分类号： A61K9/2072 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K9/2086 ,  A61K9/2095 ,  A61K9/2846 ,  A61K9/2866 ,  A61K31/4439 ,  A61K31/616

摘要： A dry-coated tablet 1 comprises an inner core 2 which contains an active component and an outer layer 3 which contains powdery solid components and coats the inner core 2. Openings 8c and 9c are formed in circular surfaces 2a and 2b respectively of the inner core 2, wherein each of the openings is larger than the average particle size of a component the average particle size of which is the smallest of the powdery solid components contained in the outer layer 3, and the inner surface 3a of the outer layer 3 penetrates in the openings 8c and 9c.

公开(公告)号：US20220144949A1

公开(公告)日：2022-05-12

申请号：US17435931

申请日：2020-03-05

申请人： TAKEDA PHARMACEUTICAL LIMITED COMPANY

发明人： Robert B. DUBRIDGE ,  Anand PANCHAL

IPC分类号： C07K16/28 ,  A61P35/00

摘要： Provided herein are compositions of conditionally activated binding proteins containing Fc regions such that the proteins target tumor antigens. Also provided are methods for coexpressing and purifying such conditionally activated binding proteins. Methods of treating cancer by administering the conditionally activated binding proteins to a patient are also described.